Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial

A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy. We evaluated the relative efficacy and safety of fentanyl matrix...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang Ju Hwang, Jae Hyup Lee, Jung-Hoon Kim, Sang Hyuk Min, Kun-Woo Park, Hyoung-Yeon Seo, Kwang-Sup Song
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2019/4905013
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554833956044800
author Chang Ju Hwang
Jae Hyup Lee
Jung-Hoon Kim
Sang Hyuk Min
Kun-Woo Park
Hyoung-Yeon Seo
Kwang-Sup Song
author_facet Chang Ju Hwang
Jae Hyup Lee
Jung-Hoon Kim
Sang Hyuk Min
Kun-Woo Park
Hyoung-Yeon Seo
Kwang-Sup Song
author_sort Chang Ju Hwang
collection DOAJ
description A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy. We evaluated the relative efficacy and safety of fentanyl matrix and gabapentin for the treatment of chronic neuropathic pain of radicular origin. The study was designed as a randomized blind multicentered parallel-group noninferiority trial. A total of 108 patients with moderate-to-severe pain (≥4 intensity on an 11-point numeric rating scale) were randomly prescribed either fentanyl matrix or gabapentin over a period of 56 days. In the primary analysis, the noninferiority of fentanyl matrix treatment was evaluated in relation to the efficacy of gabapentin based on the pain intensity difference (PID) at 56 days after the first dose of the drugs. Secondary endpoints included pain relief, improvement in functional status (the Korean-Oswestry Disability Index (K-ODI)), improvement in depressive symptoms (Korean-Beck Depression Index (K-BDI)) between the 28th and 56th day, and adverse events (AEs). Analysis of the primary efficacy endpoint established the noninferiority of fentanyl matrix compared with gabapentin, with no statistically significant difference observed in the PID after 56 days for the two treatment groups. Similarly, analysis of pain relief revealed no significant differences between the groups on days 28 and 56. There was no difference in the K-ODI and K-BDI between the groups during the study period. The overall incidence of at least one AE was similar for fentanyl matrix (67.3%) and gabapentin (69.6%). The most commonly reported AEs for patients treated with fentanyl matrix and gabapentin included dizziness (30.8% vs. 44.6%, respectively), somnolence (26.9% vs. 35.7%), and constipation (15.4% vs. 17.9%). This study demonstrated that the analgesic effect of fentanyl matrix is noninferior in comparison with gabapentin and supports the use of fentanyl matrix as an effective and safe treatment for moderate-to-severe chronic neuropathic pain. This trial is registered with NCT01127100.
format Article
id doaj-art-5730e5593afe4853be8f097119a11c6f
institution Kabale University
issn 1203-6765
1918-1523
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Pain Research and Management
spelling doaj-art-5730e5593afe4853be8f097119a11c6f2025-02-03T05:50:22ZengWileyPain Research and Management1203-67651918-15232019-01-01201910.1155/2019/49050134905013Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority TrialChang Ju Hwang0Jae Hyup Lee1Jung-Hoon Kim2Sang Hyuk Min3Kun-Woo Park4Hyoung-Yeon Seo5Kwang-Sup Song6Department of Orthopaedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of KoreaDepartment of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul, Republic of KoreaDepartment of Orthopaedic Surgery, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of KoreaDepartment of Orthopaedic Surgery, Dankook University Hospital, Cheonan, Republic of KoreaDepartment of Orthopaedic Surgery, Bundang Chuk Hospital, Seongnam, Republic of KoreaDepartment of Orthopaedic Surgery, Chonnam National University Hospital, Gwangju, Republic of KoreaDepartment of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Republic of KoreaA number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy. We evaluated the relative efficacy and safety of fentanyl matrix and gabapentin for the treatment of chronic neuropathic pain of radicular origin. The study was designed as a randomized blind multicentered parallel-group noninferiority trial. A total of 108 patients with moderate-to-severe pain (≥4 intensity on an 11-point numeric rating scale) were randomly prescribed either fentanyl matrix or gabapentin over a period of 56 days. In the primary analysis, the noninferiority of fentanyl matrix treatment was evaluated in relation to the efficacy of gabapentin based on the pain intensity difference (PID) at 56 days after the first dose of the drugs. Secondary endpoints included pain relief, improvement in functional status (the Korean-Oswestry Disability Index (K-ODI)), improvement in depressive symptoms (Korean-Beck Depression Index (K-BDI)) between the 28th and 56th day, and adverse events (AEs). Analysis of the primary efficacy endpoint established the noninferiority of fentanyl matrix compared with gabapentin, with no statistically significant difference observed in the PID after 56 days for the two treatment groups. Similarly, analysis of pain relief revealed no significant differences between the groups on days 28 and 56. There was no difference in the K-ODI and K-BDI between the groups during the study period. The overall incidence of at least one AE was similar for fentanyl matrix (67.3%) and gabapentin (69.6%). The most commonly reported AEs for patients treated with fentanyl matrix and gabapentin included dizziness (30.8% vs. 44.6%, respectively), somnolence (26.9% vs. 35.7%), and constipation (15.4% vs. 17.9%). This study demonstrated that the analgesic effect of fentanyl matrix is noninferior in comparison with gabapentin and supports the use of fentanyl matrix as an effective and safe treatment for moderate-to-severe chronic neuropathic pain. This trial is registered with NCT01127100.http://dx.doi.org/10.1155/2019/4905013
spellingShingle Chang Ju Hwang
Jae Hyup Lee
Jung-Hoon Kim
Sang Hyuk Min
Kun-Woo Park
Hyoung-Yeon Seo
Kwang-Sup Song
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial
Pain Research and Management
title Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial
title_full Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial
title_fullStr Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial
title_full_unstemmed Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial
title_short Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial
title_sort gabapentin versus transdermal fentanyl matrix for the alleviation of chronic neuropathic pain of radicular origin a randomized blind multicentered parallel group noninferiority trial
url http://dx.doi.org/10.1155/2019/4905013
work_keys_str_mv AT changjuhwang gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial
AT jaehyuplee gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial
AT junghoonkim gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial
AT sanghyukmin gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial
AT kunwoopark gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial
AT hyoungyeonseo gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial
AT kwangsupsong gabapentinversustransdermalfentanylmatrixforthealleviationofchronicneuropathicpainofradicularoriginarandomizedblindmulticenteredparallelgroupnoninferioritytrial